Gilead Sciences IncNASDAQ:GILD
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc AMGN | 79.2B | 17.9x | +15.03% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| AbbVie Inc ABBV | 74.7B | 13.9x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Biogen Idec Inc BIIB | 53.8B | 36.0x | +23.67% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Celgene Corp CELG | 52.1B | 37.9x | +43.82% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc REGN | 26.2B | 36.1x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
| Headquarters | 333 Lakeside Drive FOSTER CITY, CA, United States 94404 |
|---|---|
| Phone | 650-574-3000 |
| Fax | 650-578-9264 |
EXECUTIVE OFFICERS
| Chairman of the Board, Chief Executive Officer | John Martin |
|---|---|
| President, Chief Operating Officer | John Milligan |
| Chief Financial Officer, Senior Vice President | Robin Washington |
| Executive Vice President - Research and Development, Chief Scientific Officer | Norbert Bischofberger |
| Executive Vice President - Corporate and Medical Affairs | Gregg Alton |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $85.9B | Beta | 0.52 |
|---|---|---|---|
| Revenue (TTM) | $10.0B | EPS | $1.51 |
| Shares Out. | 1.5B | Book Value | $6.13 |
| Dividend Yield | 0.00% | P/E | 37.3x |
| Annual Dividend Rate | $0.00 | Price/Sales (TTM) | 8.6 |
| Ex-Div Date | 1/1/01 | P/Cash Flow (TTM) | 27.1x |
| Pay Date | 1/1/01 | Operating Margin | 42.63% |
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
